Related Experiment Video

Updated: Jun 27, 2026

Differential Effects of Lipid-lowering Drugs in Modulating Morphology of Cholesterol Particles
09:15

Differential Effects of Lipid-lowering Drugs in Modulating Morphology of Cholesterol Particles

Published on: November 10, 2017

Should we treat all primary prevention patients with statins?

Robert Guthrie1

  • 1Department of Emergency Medicine, The Ohio State University, Columbus, OH 43212, USA. guthrie.1@osu.edu

Current Atherosclerosis Reports
|December 17, 2008
PubMed

Insights

3-Hydroxy-3-methylglutary coenzyme A (HMG-CoA) reductase inhibitors are proven to reduce cardiac events. Aggressive use of these statin medications is the recommended treatment for lipid abnormalities, as combination therapies lack supporting evidence for improved cardiac event reduction.

Area of Science:

  • Cardiovascular Medicine
  • Pharmacology

Background:

  • 3-Hydroxy-3-methylglutary coenzyme A (HMG-CoA) reductase inhibitors, commonly known as statins, are widely used for cholesterol management.
  • Evidence supports statins in reducing cardiac events in high-risk and medium-risk populations.

Purpose of the Study:

  • To evaluate the efficacy of HMG-CoA reductase inhibitors in preventing initial cardiac events.
  • To assess the evidence for combination therapies involving statins for improved cardiac event reduction.

Main Methods:

  • Review of existing clinical evidence and studies on HMG-CoA reductase inhibitors and combination lipid-lowering therapies.
  • Analysis of data regarding the impact of these treatments on initial cardiac events.

Main Results:

  • HMG-CoA reductase inhibitors have demonstrated effectiveness in reducing cardiac events.
  • Limited or no evidence exists to support the use of other cholesterol-lowering medications for initial cardiac event protection.
  • Evidence for improved reduction of initial cardiac events with combination therapies (statins plus second agents) is lacking.

Conclusions:

  • Aggressive use of HMG-CoA reductase inhibitors is the established and proven treatment for lipid abnormalities in primary prevention patients.
  • Current evidence does not support the routine use of combination therapies for enhanced initial cardiac event reduction.

Related Concept Videos

Lipid-Lowering Drugs: Statins and Miscellaneous Agents01:20

Lipid-Lowering Drugs: Statins and Miscellaneous Agents

Hyperlipidemia, a medical condition often referred to as high cholesterol, is characterized by abnormally elevated levels of lipids in the bloodstream. When present in excess, these lipids, specifically cholesterol and triglycerides, can lead to serious health complications, often involving cardiovascular diseases. Illnesses like atherosclerosis, heart attacks, and pancreatitis have all been linked to untreated hyperlipidemia. This means controlling and regulating cholesterol and triglyceride...
Atherosclerosis III: Management01:26

Atherosclerosis III: Management

Management of atherosclerosis involves an integrated strategy encompassing pharmacological treatment, surgical interventions, lifestyle changes, and nutrition therapy to address the multifactorial nature of the disease.Pharmacological TherapyA cornerstone of atherosclerosis management is the use of pharmacological agents. Statins, such as atorvastatin, are pivotal in inhibiting HMG-CoA reductase, an enzyme that catalyzes an initial step in cholesterol synthesis in the liver. This reduction in...
Preventive Healthcare Services01:30

Preventive Healthcare Services

Preventive healthcare services keep people healthy via frequent check-ups, screening, and counseling. They primarily aid in disease prevention rather than treating an acute or chronic illness. Preventive treatment also keeps individuals productive and energetic, allowing them to work well into their retirement years. Examples of preventive care services include:
Coronary Artery Disease IV: Preventive Measures01:26

Coronary Artery Disease IV: Preventive Measures

Effective preventive measures for coronary artery disease (CAD) focus on controlling modifiable risk factors, including cholesterol abnormalities and lifestyle changes.Cholesterol ManagementFirst, the Mediterranean diet and the American Heart Association advocate for maintaining low-density lipoprotein (LDL) cholesterol levels below 100 mg/dL, with a more stringent recommendation of below 70 mg/dL for individuals at high risk. LDL cholesterol, often termed "bad cholesterol," can lead to the...
Coronary Artery Disease V: Interprofessional Care01:27

Coronary Artery Disease V: Interprofessional Care

Interprofessional care for coronary artery disease includes pharmacological therapy and revascularization procedures.Pharmacological therapy for Coronary Artery Disease (CAD) aims to manage symptoms, prevent complications, and improve patient outcomes through various classes of medications:Antiplatelet Agents:Aspirin and Clopidogrel: These medications inhibit platelet aggregation, preventing blood clots, which is crucial for avoiding heart attacks and strokes. Doctors often prescribe these...
Levels of Health Promotion and Illness Prevention01:26

Levels of Health Promotion and Illness Prevention

Health promotion allows a person to control the determinants of health, resulting in an improved health status. It enhances the quality of life and reduces premature deaths. Health promotion and illness prevention programs help people make beneficial choices to reduce the risk of disease and disabilities. There are three health promotion and illness prevention levels: primary, secondary, and tertiary prevention.
In primary prevention, actions taken before disease onset prevent the disease from...